Prostate Cancer Program 2018 Annual Research Cancer Program 2018... Poster-board Title Majid Shahana

  • View
    0

  • Download
    0

Embed Size (px)

Text of Prostate Cancer Program 2018 Annual Research Cancer Program 2018... Poster-board Title Majid Shahana

  • Prostate Cancer Program

    2018 Annual Research Retreat

    Abstracts

    Alphabetical by last name of presenting author

  • Posterboard Assignments by Author Last Name

    Last Name⬇ First Name Room Poster-board Title

    Balakrishnan Ashwin Cypress 1 An SMS-Based Periprocedural Intervention for Patients Undergoing Prostate Biopsy: Impact on Clinical Utilization, Patient/Provider Communication, and Patient Satisfaction Belair Cassandra Cypress 2 Improving Prostate Cancer Outcome Prediction Through Noninvasive exRNA Assessment: Year 2 Update Bhagirath Divya Cypress 3 Role of Exosomes in Inducing Neuroendocrine Differentiation in Advanced Prostate Cancer Borno Hala Cypress 4 A Pilot Feasibility Study for Improving Patient Access to Cancer Clinical Trials (Impact Study) Borno Hala Cypress 5 Differential Utilization of Medical versus Surgical Androgen Deprivation therapy for Metastatic Prostate Cancer

    Borno Hala Cypress 6 Trial Library – A Pilot Study to Examine the Feasibility, Acceptability, and Preliminary Estimates of Efficacy for a Clinical Trial Online Matching Website on Patient-Prompted Conversations Regarding Prostate Cancer Clinical Trials

    Cavazos Taylor Cypress 7 Integrating Genetic information With Machine Learning to Predict Which Prostate Cancer Cases Should Not Be Immediately Treated.

    Chen Emmalyn Cypress 8 Quantification of Cell-Free DNA Levels as a Potential Screening and Diagnostic Marker for Localized and Metastatic Prostate Cancer Chou Jonathan Cypress 9 IMPACT: A Phase II Trial of Combination Immunotherapy in Patients With Metastatic Cancers and CDK12 Mutations Das Rajdep Cypress 10 Investigating the Role of the Long Non-Coding RNA Schlap1 in Prostate Cancer Metastasis Datta Debajyoti Cypress 11 Linking Clinical Molecular Profiles of Tumors to the Electronic Medical Record Fu Qi Cypress 12 Identification of Small Molecule Inhibitors of a Novel Regulatory Pathway of Immune Checkpoint Proteins Greenland Nancy Cypress 13 Expansile Cribriform Gleason Pattern 4 has Worse Outcomes at Prostatectomy than Glomerulation Gleason Pattern 4 Gu Wei Cypress 14 Incidental Detection of Malignancies in Metagenomics Cell-Free DNA Testing Hashimoto Yutaka Cypress 15 Up-Regulation of miR-130b Is Involved in Prostate Cancer Racial Disparity Thorough FHIT Pathway inactivation Herlemann Annika Cypress 16 Comparison of TRUS-Targeted vs. MRI-Targeted vs. Systematic Prostate Biopsy in Detecting Prostate Cancer Jeong Chang Wook Cypress 17 Standard Gamble Utility Measurement from Prostate Cancer Long-Term Survivors: Results from the CaPSURE Registry

    Jeong Chang Wook Cypress 18 Validation of the Utility Weighting Function for the Patient-Oriented Prostate Utility Scale (PORPUS-U) Using the Capsure Quality of Life Supplementary Study Data

    Kachuri Linda Cypress 19 Disentangling the Relationship Between Genetic Predictors of PSA, Prostate Cancer Susceptibility, and Benign Prostatic Hyperplasia

    Kido Tatsuo Cypress 20 The C-Terminal Acidic Domain of TSPX, an X-Linked Tumor Suppressor, Plays Crucial Roles in the Functional Networks of Prostate Cancer

    Kith Glenda Hawthorn 30 A Systematic Review of Observational Studies Assessing Outcomes of Prostate Cancer Patients on Active Surveillance: An Examination of Adherence To Protocols Korenchan David Cypress 21 Hyperpolarized In Vivo pH Imaging Reveals Grade-Dependent Acidification in Prostate Cancer

    Korn Natalie Cypress 22 The Rate of Hyperpolarized [1-13C] Pyruvate To [1-13C] Lactate Conversion Distinguishes High-Grade from Low-Grade Prostate Cancer in Patients

    Kothari Vishal Cypress 23 Maternal Embryonic Leucine Zipper Kinase (MELK) Is A Novel Therapeutic Target and a Biomarker of Aggressive Prostate Cancer Langlais Crystal Cypress 24 Obesity and Prostate Cancer Recurrence Following Radical Prostatectomy Li Hui Hawthorn 29 The Long Noncoding RNA PLUTO-201 Is Associated With Prostate Cancer Progression and Metastasis

    Lisker Sarah Hawthorn 30 A Systematic Review of Observational Studies Assessing Outcomes of Prostate Cancer Patients on Active Surveillance: An Examination of Adherence To Protocols (With Glenda Kith)

  • Posterboard Assignments by Author Last Name

    Last Name⬇ First Name Room Poster-board Title

    Majid Shahana Hawthorn 32 Controversial Role of Micro-RNA-588 in Prostate Cancer Meyers Travis Hawthorn 33 inflammatory Bowel Disease and Prostate Cancer Risk: A Mendelian Randomization Study Moroz Anna Hawthorn 34 Measuring PD-L1 Expression With ImmunoPET Nguyen Hao Hawthorn 50 Does PI-RADS V2 Scores Predict Adverse Surgical Pathology At Radical Prostatectomy

    Nguyen Hao Hawthorn 51 Evaluating MRI Fusion Biopsy Vs Systematic Ultrasound Guided Biopsy in Predicting High Grade Cancer At Time of Radical Prostatectomy

    Nguyen Hao Hawthorn 52 Targeting the Translational oncogenic Program of the Major Cap-Binding Protein eIF4E in Metastatic Castration Resistant Prostate Cancer Nicholson Lowell Hawthorn 35 A Phase 1/2 Trial of Ibrutinib as Neoadjuvant Therapy in Patients With Localized Prostate Cancer Noworolski Susan Hawthorn 36 Characterizing Sparse and Dense Prostate Cancers on Whole-Mount Histopathology and on Multiparametric MRI Oh David Cypress 25 Single Cell Discrimination of Immunotherapy-Induced Changes in the Prostate Tumor Microenvironment Palmer Nynikka Hawthorn 38 An Ethnographic Study of African American Men's Prostate Cancer Treatment Decision-Making Palmer Nynikka Hawthorn 39 The Communication Chasm and Prostate Cancer Diagnoses: An Ethnographic Study With African American Men Paris Pamela Hawthorn 40 Multiple Biomarkers Independently and Additively Predict Prostate Cancer Pathology Outcomes Quigley David Hawthorn 31 Genomic Hallmarks and Structural Variation in Metastatic Prostate Cancer Robinson Troy Hawthorn 41 Targeting Androgen Receptor and the ACK1 Signaling Axis in Castration-Resistant Prostate Cancer Shiina Marisa Hawthorn 42 High Expression of miR-182 Promotes Prostate Cancer Aggressiveness in African-Americans Compared to Caucasians Shkedi Arielle Hawthorn 37 Identification of Molecular Chaperone Targets for Castration-Resistant Prostate Cancer Treatment

    Small Eric Hawthorn 44 Health-Related Quality of Life (HRQoLl) After Disease Progression in SPARTAN: A Phase 3 Trial of Apalutamide (APA) Versus Placebo (PBO) in Men With Nonmetastatic Castration-Resistant Prostate Cancer (nmCRPC)

    Small Eric Hawthorn 45 Prostate-Specific Antigen (PSA) Outcomes in Patients (Pts) With Nonmetastatic Castration-Resistant Prostate Cancer (Nmcrpc) Treated With Apalutamide (APA): Results From Phase 3 SPARTAN Study

    Small Eric Hawthorn 46 SPARTAN, a Phase 3 Double-Blind, Randomized Study of Apalutamide (APA) Versus Placebo (PBO) in Patients (Pts) With Nonmetastatic Castration-Resistant Prostate Cancer (Nmcrpc) Sun Jinny Hawthorn 43 Resistance to Androgen Deprivation Therapy Leads to Altered Metabolism in Prostate Cancer Cell and Murine Models Tanaka Yuichiro Hawthorn 47 Functional Significance of Catechol-O-Methyltransferase Gene in Prostate Cancer Washington Samuel Cypress 26 MRI-Based Prostate Specific Antigen Density Predicts Gleason Score Upgrade in An Active Surveillance Cohort Xu Melody Hawthorn 48 Genomic Risk Predicts for Molecular Imaging Detected Metastatic Nodal Disease in Prostate Cancer Xu Melody Hawthorn 49 Single Fraction Brachytherapy as Monotherapy for Early Stage Prostate Cancer: The UCSF Experience Yang Thao Hawthorn 55 Role of a Novel microRNA Gene at Frequently Deleted Chromosome 8p Region in Prostate Cancer

    Zhang Li Cypress 27 Tracking of Long-Term B-Cell Memory Responses Using B-Cell Receptor (BCR) Sequencing in Prostate Cancer (PC) Patients (Pts) Treated With Sipuleucel-T (Sip-T) Zhao Ning Cypress 28 Exploiting the Labile Fe(II) Pool To Image Prostate Cancer With PET

    Zuniga Kyle Hawthorn 53 The Association Between Cribriform Pattern and Adverse Pathology at Radical Prostatectomy in Prostate Cancer Patients Initially on Active Surveillance Zuniga Kyle Hawthorn 54 Trends in Complementary and Alternative Medicine Use Among Prostate Cancer Patients

  • Podium Session 2

    Clinical and Genomic Hallmarks of Treatment-Associated Small Cell Neuroendocrine Carcinoma: Data from the West Coast Prostate Cancer Dream Team Rahul Aggarwal, Paul Lloyd, Jiaoti Huang, Tomasz Beer, Li Zhang, George Thomas, Lawrence True, Joshi Alumkal, Verena Friedl, Alana Weinstein, Rob Reiter, Matt Rettig, Primo Lara, Martin Gleave, Adam Foye, Denise Playdle, Felix Feng, Kim Chi, Josh Stuart, and Eric Small Background: Genomic alterations in DNA repair genes are present in approximately 20-30% of patients with mCRPC. t-SCNC may be increasing in prevalence and is associated with adverse clinical outcomes. Potential overlap between these two subsets of mCRPC was assessed. Methods: Eligible patients (pts) underwent a metastatic tumor core needle biopsy at one of 5 centers. Tumor tissue was sent for consensus pathology call (JH, GT, LT) and targeted next- generation DNA sequencing. Chi-square test was used to compare the frequency of genomic alterations in select DNA repair genes (BRCA1, BRCA2, ATM, CDK12, RAD51, PALB2, FANCA, CHEK2, MLH1, MSH2, MLH3, and MSH6) between tumors with versus those without small cell histology. Frozen tissue from the same metastatic tumor underwent RNA sequencing (RNA- seq). Pts were prospectively followed for overall survival (OS). Results: 119 consecutive biopsies with sufficient tumor to permit histologic assessment and targeted NGS were included, including 14 biopsies (13%) with t-SCNC. In the overall cohort, DNA repair mutations were present in 41 biopsies (34%). By histologic subtype, mutations were present in 40/105 (38%) of adenocarcinoma tumors vs. only 1 of 14 (7%) b